Lncrna ANGPTL1-3 and its target microRNA-30a exhibit potency as biomarkers for bortezomib response and prognosis in multiple myeloma patients-Reference-Cited by-同舟云学术

Lncrna ANGPTL1-3 and its target microRNA-30a exhibit potency as biomarkers for bortezomib response and prognosis in multiple myeloma patients

Published:2022-05-26 Issue:1 Volume:27 Page:596-602
ISSN:1607-8454
Container-title:Hematology
language:en
Short-container-title:Hematology

Author:

Zhou Fangfang¹,Guo Liyin¹^ORCID

Affiliation:

1. Department of Hematology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China

Funder

Expression and significance of PI3k/Akt signal molecules in multiple myeloma stem cells

Publisher

Informa UK Limited

Subject

Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/16078454.2022.2072062

Reference30 articles.

1. Patient population with multiple myeloma and transitions across different lines of therapy in the USA: an epidemiologic model

2. Current approaches to management of high‐risk multiple myeloma

3. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. LINC01432binds to CELF2 in newly diagnosed multiple myeloma promoting short progression-free survival to standard therapy;2024-06-30

2. Highlighting the role of long non-coding RNA (LncRNA) in multiple myeloma (MM) pathogenesis and response to therapy;Medical Oncology;2024-06-07

3. Long non‑coding RNAs in multiple myeloma (Review);International Journal of Oncology;2023-05-04

4. Non-coding RNAs and exosomal ncRNAs in multiple myeloma: An emphasis on molecular pathways;European Journal of Pharmacology;2023-02